Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins

Syndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the α3β1 Integrin Via Binding Sites in Their Ectodomains

(2015) Haiyao Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The potential of heparanase as a therapeutic target in cancer

(2014) Claudio Pisano et al.   BIOCHEMICAL PHARMACOLOGY

Role of Integrin Alpha4 in Drug Resistance of Leukemia

(2014) Stephanie Shishido et al.   Frontiers in Oncology

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models

(2013) G. Cassinelli et al.   BIOCHEMICAL PHARMACOLOGY

A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma

(2013) Paola Orecchia et al.   EUROPEAN JOURNAL OF CANCER

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies

(2013) Vishnu C. Ramani et al.   FEBS Journal

Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis

(2013) Alan C. Rapraeger   FEBS Journal

Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis

(2013) Alan C. Rapraeger et al.   FEBS Journal

Characterization of Heparanase-induced Phosphatidylinositol 3-Kinase-AKT Activation and Its Integrin Dependence

(2013) Anjum Riaz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Heparan Sulfate Chains of Syndecan-1 Regulate Ectodomain Shedding

(2012) Vishnu C. Ramani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Removal of Syndecan-1 Promotes TRAIL-Induced Apoptosis in Myeloma Cells

(2012) Y.-H. Wu et al.   JOURNAL OF IMMUNOLOGY

PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model

(2012) Edward Hammond et al.   PLoS One

Role of Heparanase in Radiation-Enhanced Invasiveness of Pancreatic Carcinoma

(2011) A. Meirovitz et al.   CANCER RESEARCH

Life at the Leading Edge

(2011) Anne J. Ridley   CELL

SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis

(2011) Joseph P. Ritchie et al.   CLINICAL CANCER RESEARCH

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells

(2011) S Lamorte et al.   LEUKEMIA

M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis

(2011) He Zhou et al.   PLoS One

Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis

(2010) A. Purushothaman et al.   BLOOD

Integrin  4 1 Signaling Is Required for Lymphangiogenesis and Tumor Metastasis

(2010) B. Garmy-Susini et al.   CANCER RESEARCH

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis

(2010) Uri Barash et al.   FEBS Journal

Interaction of Syndecan and α6β4 Integrin Cytoplasmic Domains

(2010) Haiyao Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Expression and Activity

(2010) Vishnu C. Ramani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation

(2010) D. M. Beauvais et al.   JOURNAL OF CELL SCIENCE

Pre-clinical and clinical significance of heparanase in Ewing’s sarcoma

(2010) Itay Shafat et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The evolution and impact of therapy in multiple myeloma

(2010) Jacob P. Laubach et al.   MEDICAL ONCOLOGY

The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma

(2010) V. Scudla et al.   NEOPLASMA

Tumorigenic and adhesive properties of heparanase

(2010) Flonia Levy-Adam et al.   SEMINARS IN CANCER BIOLOGY

Structure-Function Approach Identifies a COOH-Terminal Domain That Mediates Heparanase Signaling

(2009) L. Fux et al.   CANCER RESEARCH

Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumorsin Vivo

(2009) Yekaterina B. Khotskaya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Syndecan-1 regulates αvβ3and αvβ5integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor

(2009) DeannaLee M. Beauvais et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

(2009) Chun-Jen Liu et al.   JOURNAL OF HEPATOLOGY

Heparanase: busy at the cell surface

(2009) Liat Fux et al.   TRENDS IN BIOCHEMICAL SCIENCES

Localized α4 Integrin Phosphorylation Directs Shear Stress–Induced Endothelial Cell Alignment

(2008) Lawrence E. Goldfinger et al.   CIRCULATION RESEARCH

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

(2008) M. B. Meads et al.   CLINICAL CANCER RESEARCH

Structural and Cell Adhesion Properties of Zebrafish Syndecan-4 Are Shared with Higher Vertebrates

(2008) James R. Whiteford et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma

(2008) Anurag Purushothaman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4–VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production

(2008) Masahiro Abe et al.   JOURNAL OF BONE AND MINERAL METABOLISM